PharmacoEconomics & Outcomes News

, Volume 832, Issue 1, pp 29–29 | Cite as

Recombinant Factor VIII Fc-fusion protein cost effective

Clinical study


  1. Bullement A, et al. Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data. PharmacoEconomics-Open : 6 Jul 2019. Available from: URL:

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations